Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026
Sutro Biopharma, Inc. (STRO)
Last sutro biopharma, inc. earnings: 11/8 07:00 am
Check Earnings Report
Company Research
Source: GlobeNewswire
STRO-004 demonstrates robust and consistent antitumor activity across multiple TF-expressing solid tumor PDX models, with improved efficacy versus benchmark ADCs STRO-006 and STRO-227 show meaningful, dose-dependent antitumor activity across solid tumor models Presentation of TROP2-targeted immunostimulatory ADC program partnered with Astellas highlights the potential of Sutro’s platform for developing dual-payload ADCs SOUTH SAN FRANCISCO, Calif., April 19, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced promising preclinical data across its pipeline of next- generation ADCs in five posters and one oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026. Of note, results from a preclinical study of STRO-004, its DAR8 Topo1 ADC targeting Tissue Factor (TF), were reviewed today in an
Show less
Read more
Impact Snapshot
Event Time:
STRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
STRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
STRO alerts
High impacting Sutro Biopharma, Inc. news events
Weekly update
A roundup of the hottest topics
STRO
News
- Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026 [Yahoo! Finance]Yahoo! Finance
- Sutro Biopharma (STRO) had its price target raised by Citizens Jmp from $23.00 to $35.00. They now have a "market outperform" rating on the stock.MarketBeat
- Sutro Biopharma (STRO) had its "outperform" rating reaffirmed by Citigroup Inc..MarketBeat
- Sutro Biopharma (STRO) is now covered by Leerink Partners. They set an "outperform" rating and a $38.00 price target on the stock.MarketBeat
- Sutro Biopharma (STRO) was upgraded by Truist Financial Corporation to "strong-buy".MarketBeat
STRO
Earnings
- 5/8/25 - Miss
STRO
Sec Filings
- 4/2/26 - Form EFFECT
- 4/1/26 - Form 424B3
- 3/23/26 - Form S-3
- STRO's page on the SEC website